Drug updated on 10/29/2024
| Dosage Form | Injection (intravenous; 150 mg/15 mL of 0.9% sodium chloride); Tablet (oral: 600 mg) |
| Drug Class | Pleuromutilin antibacterials |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Omadacycline demonstrated the highest clinical treatment success and microbiological treatment success compared to other drugs, establishing it as the most effective option for treating complicated skin and soft tissue infections (cSSTIs).
- Lefamulin, while effective, ranked lower in both clinical and microbiological treatment success compared to omadacycline and avarofloxacin, indicating a need for further evaluation in this context.
- The study does not provide specific information regarding the effectiveness of lefamulin among different population types and subgroups, limiting insights into its application across diverse patient groups.
- Lefamulin is associated with the lowest risk of severe adverse events (AEs) among the assessed drugs, indicating a favorable safety profile compared to omadacycline, which has a moderately safe profile but is not the safest option.
- No specific safety concerns or adverse effects were detailed for different population types and subgroups in the study.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Xenleta (lefamulin) Prescribing Information. | 2021 | Nabriva Therapeutics US Inc., Fort Washington, PA |